Inverna Therapeutics ApS

CVR 45161641 · Private limited company (ApS) · Active · Medium risk

Inverna Therapeutics ApS is a Private limited company (ApS), founded on , based in Odense M. The company is registered in the industry forskning og eksperimentel udvikling inden for naturvidenskab og teknik. Our model estimates a bankruptcy risk of 1.9% over the next 12 months, which is 1.3 times the average for Danish companies. 2 annual reports have been published. The latest annual report (31 Dec 2025) shows equity of DKK 3.8m and a net result of DKK -11.2m. CEO: Poul Sørensen.

Bankruptcy risk for Inverna Therapeutics ApS

1.9%
probability of bankruptcy within 12 months
Medium risk

1.3 × the average (1.41%) · higher risk than 82% of active Danish companies

Lowest riskHighest risk

Increases the risk

Age (years)2 yrs · bankruptcy rate 18.9%2.1×
Published annual reports2 · bankruptcy rate 16.7%1.9×
Return on assets< -20% · bankruptcy rate 16.7%1.9×
Number of auditors (historical)0 · bankruptcy rate 12.5%1.4×
CEO's other companies0 · bankruptcy rate 10.9%1.2×
Time since new CEO2–5 yrs · bankruptcy rate 10.8%1.2×
Audit opted outYes · bankruptcy rate 10.4%1.2×
Auditor registered in CVRNo · bankruptcy rate 10.4%1.2×

Reduces the risk

Equity vs. share capital5+× · bankruptcy rate 2.5%0.28×
Current ratio200%–500% · bankruptcy rate 3.4%0.39×
Equity ratio40%–60% · bankruptcy rate 4.6%0.52×
Negative equityNo · bankruptcy rate 5.1%0.58×
Share of late annual reports< 0.01% · bankruptcy rate 5.2%0.59×
Auditor's statementCompilation · bankruptcy rate 5.6%0.64×
Registered owners4+ · bankruptcy rate 5.7%0.65×
Reporting classReporting class B · bankruptcy rate 5.7%0.65×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
45161641
Status
Active
Company type
Private limited company (ApS)
Founded
(2 years)
Address
c/o Science Ventures Denmark A/S, Cortex Park 26E, 1.
5230 Odense M
Municipality
Odense
Industry
Forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721000)
Bankruptcies in the industry: Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Share capital
DKK 105k
Auditor
REVISIONSFIRMAET JAN KRISTENSEN REGISTRERET REVISIONSANPARTSSELSKAB
Audit opted out
Yes

Warning signs

Annual reports filed late0 of 2
Missing annual reportNo
Negative equityNo
Equity ratio54.9%
Current ratio222%
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address41
Going-concern uncertaintyNo

Financials and key figures

Financial year20252024
Gross profitDKK -14.2mDKK -159k
Net profitDKK -11.2mDKK -159k
EquityDKK 3.8mDKK 3.6m
Total assetsDKK 6.9mDKK 3.8m
CashDKK 3.7m–
Short-term debtDKK 3.1m–
Avg. employees1–

Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · REVISIONSFIRMAET JAN KRISTENSEN REGISTRERET REVISIONSANPARTSSELSKAB.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025163
22 Oct 2024 – 31 Dec 202456

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOPoul SørensenCurrent
BoardPoul SørensenCurrent
BoardBrage Storstein AndresenCurrent
BoardJens Kristian DamsgaardCurrent
BoardDaniel SobralCurrent
BoardMads Aaboe Jensen
BoardPontus Fredrik Gunnar Klein
Owner (5%)SCIENCE VENTURES DENMARK A/SCurrent
Owner (5%)Thomas Koed DoktorCurrent
Owner (10%)Brage Storstein AndresenCurrent
Owner (50%)Argobio SASCurrent
Owner (15%)Thomas Koed Doktor
Owner (10%)Lise Lolle Holm
Owner (25%)Brage Storstein Andresen
Owner (10%)Ulrika Simone Spangsberg Petersen
Owner (10%)SCIENCE VENTURES DENMARK A/S
Owner (10%)BlueBio Holding ApS
Owner (5%)Argobio SAS
Owner (10%)Thomas Koed Doktor
Owner (5%)Lise Lolle Holm
Owner (15%)Brage Storstein Andresen
Owner (5%)Ulrika Simone Spangsberg Petersen
Owner (5%)BlueBio Holding ApS
Owner (33%)Argobio SAS
FounderThomas Koed DoktorCurrent
FounderLise Lolle HolmCurrent
FounderBrage Storstein AndresenCurrent
FounderUlrika Simone Spangsberg PetersenCurrent
FounderSCIENCE VENTURES DENMARK A/SCurrent
FounderBlueBio Holding ApSCurrent
FounderArgobio SASCurrent

The CEOs' other companies

Poul Sørensen – 1 other companies

Address history (0 moves)

c/o Science Ventures Denmark A/S, Cortex Park 26E, 1., 5230 Odense M

Other companies at the same address

Similar companies in Odense

Questions and answers about Inverna Therapeutics ApS

Has Inverna Therapeutics ApS gone bankrupt?

No, Inverna Therapeutics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Inverna Therapeutics ApS?

Our model estimates a bankruptcy risk of 1.9% over the next 12 months (medium risk), which is 1.3 times the average for Danish companies.

Who is the CEO of Inverna Therapeutics ApS?

Poul Sørensen is the CEO of Inverna Therapeutics ApS.

Who is the auditor of Inverna Therapeutics ApS?

Inverna Therapeutics ApS most recently used REVISIONSFIRMAET JAN KRISTENSEN REGISTRERET REVISIONSANPARTSSELSKAB.

When was Inverna Therapeutics ApS founded?

Inverna Therapeutics ApS was founded on 22 October 2024.

What is the equity of Inverna Therapeutics ApS?

Equity was DKK 3.8m according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.